Nutraceutical Approach for the Management of Diabetic Neuropathy

Author(s): Giovanni Ragozzino, Umberto Di Maio, Maria Potenza

Painful diabetic neuropathy (pDN) is a common type of peripheral neuropathic pain and it's defined as pain that is a direct consequence of abnormalities in the peripheral somatosensory system in individuals with diabetes. Antidiabetic drugs improve the glycemic profile but do not act on the symptoms of pDN, while the drugs commonly used for the symptoms of diabetic neuropathy (antidepressants and anticonvulsants) cause several side effects including dizziness, constipation, somnolence and loss of appetite, so it’s important to have nutraceutical tools capable of delaying or reducing the pharmacological approach. The aim of the present retrospective clinical survey was to evaluate the effect of Epiderali® plus in patients undergoing therapy with hypoglycemic drugs showing symptoms of diabetic neuropathy not well controlled with the pharmacological treatments (T0 score for motion questionnaires). After three months of treatment and still up to six months with Epiderali® plus of treatment the blood parameters were controlled without collateral interactions with pharmacological treatments. Moreover, using three different standardized questionnaires all the symptomatology related to motion, pain and quality of life was significantly improved. After a more complex clinical investigation it could be possible to consider Epiderali® plus as novel therapeutic tool for the management of motorial neuropathy and pain in patients with diabetes neuropathy.